Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA7 | P43166 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8955219 | 0.86 | CA12 (0.35) | CA1CA2CA7CA9CA12 | |
| SCHEMBL9161008 | 0.84 | LTA4H (0.42) | CA1CA2CA7CA9CA12 | |
| SCHEMBL27822368 | 0.81 | CA1 (0.42) | CA1CA2CA7CA9CA12 | |
| SCHEMBL28657116 | 0.81 | CES2 (0.45) | CA1CA2CA7CA9CA12 | |
| SCHEMBL1070797 | 0.80 | ABCB11 (0.58) | TDP1L3MBTL1TSHRCYP1A2MAPT | |
| SCHEMBL28657119 | 0.80 | CA1 (0.47) | CA1CA2L3MBTL1TSHRCYP1A2 | |
| SCHEMBL12480922 | 0.78 | ALDH1A3 (0.47) | MAPK1ALDH1A1CYP2D6CYP2C19GAA | |
| SCHEMBL16859725 | 0.78 | SLC2A1 (0.71) | CA1CA2CA7CA9CA12 | |
| SCHEMBL19077747 | 0.78 | CA1 (0.65) | CA1CA2CA7CA9CA12 | |
| SCHEMBL21162070 | 0.78 | TSHR (0.34) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1572 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12623988-B2 | Scaleable preparation of polyketides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-12 | — | — | US | claimed |
| EP-4626872-A1 | CHEMOENZYMATIC SYNTHESIS OF POLYKETIDES | Aspera Biomedicines, Inc. (US) | 2025-10-08 | — | — | EP | claimed |
| US-12378278-B2 | Mimetics of heparin oligosaccharides | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2025-08-05 | — | — | US | claimed |
| EP-3707147-B1 | NEW SYNTHETIC AGONISTS OF TLR4 RECEPTOR | UNIV DEGLI STUDI DI MILANO BICOCCA (IT) | 2025-03-05 | — | — | EP | claimed |
| US-12139627-B2 | Perovskite ink formulations | EXCYTON LIMITED (GB) | 2024-11-12 | — | — | US | claimed |
| EP-4114649-B1 | METHOD FOR POST-PROCESSING AN ADDITIVELY MANUFACTURED PART | ADDITIVE MANUFACTURING TECH LTD (GB) | 2024-06-12 | — | — | EP | claimed |
| WO-2024119114-A1 | CHEMOENZYMATIC SYNTHESIS OF POLYKETIDES | ASPERA BIOMEDICINES, INC. (US) | 2024-06-06 | — | — | WO | claimed |
| EP-4356894-A1 | SUSTAINABLE PRODUCT WITH MALODORS | Beiersdorf AG (DE) | 2024-04-24 | — | — | EP | claimed |
| US-11919262-B2 | Method for post-processing an additively manufactured part | Additive Manufacturing Technologies Limited (GB) | 2024-03-05 | — | — | US | claimed |
| CN-112979602-B | Preparation method of intermediate of antiviral drug | 广东东阳光药业股份有限公司 | 2024-01-16 | — | — | CN | claimed |
| WO-2002090479-A1 | PERFUMED PARTICLES AND ARTICLES CONTAINING THE SAME | THE PROCTER & GAMBLE COMPANY (US) | 2002-11-14 | — | — | WO | claimed |
| EP-1001951-B1 | THIAZOLE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND USE | SCHERING AG (DE) | 2002-09-25 | — | — | EP | claimed |
| US-5393876-A | Process for producing maltooligosaccharide derivatives | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1995-02-28 | — | — | US | claimed |
| EP-0566366-A2 | Process for producing maltooligosaccharide derivative | WAKO PURE CHEMICAL INDUSTRIES LTD (JP) | 1993-10-20 | — | — | EP | claimed |
| EP-0234348-B1 | N-GLYCOSYL AMIDE DERIVATIVES, METHOD FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | BAYER AG (DE) | 1991-05-29 | — | — | EP | claimed |
| US-4891425-A | IMMUNOSTIMULANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1990-01-02 | — | — | US | claimed |
| EP-0234348-A2 | N-glycosyl amide derivatives, method for their preparation and their use as medicaments | BAYER AG (DE) | 1987-09-02 | — | — | EP | claimed |
| EP-0054699-B1 | METHOD FOR THE CATALYTIC HYDROGENOLYSIS OF PARA-SUBSTITUTED BENZALDEHYDE-DIMETHYL ACETALS INTO THE CORRESPONDING BENZYLMETHYL ETHERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-03-14 | — | — | EP | claimed |
| US-4413149-A | COBALT CARBONYL AND A NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-11-01 | — | — | US | claimed |
| EP-0054699-A2 | Method for the catalytic hydrogenolysis of para-substituted benzaldehyde-dimethyl acetals into the corresponding benzylmethyl ethers | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-06-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12623988-B2 | Scaleable preparation of polyketides | SF3B5, RPS5, RPS25 | CA1 4876/4885CA2 4875/4885CA7 3023/4885 |
| US-12378278-B2 | Mimetics of heparin oligosaccharides | HPSE, IAPP, PYGB | CA1 136/4885CA2 3137/4885CA7 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.